Laws & Regulations in an Evolving Healthcare Marketplace Real Life Implications for Biopharmaceutical Industry

Christi Shaw

Head, US General Medicines President, Novartis Pharmaceuticals Corporation February 17, 2016





Shifting from Volume to Value






The healthcare industry is embracing change, but can only advance so far with the current infrastructure



Laws impacting shift to value-based healthcare










Stakeholders want to create new patient solutions





Thinking outside the box





Anti-kickback statutes don't always take into account current healthcare payment and delivery models

- How can we all think and work more creatively for the benefit of improved healthcare outcomes?
- How do we step out of our silos and work across the system?
- How can pharma manufacturers work more directly with ACOs or other integrated care entities?

NDHI Recommendation

Greater flexibility and new anti-kickback statute safe harbors to achieve increased quality and lower costs



We need greater flexibility to **SHARE** scientific and health economic data

 Sharing scientific and healthcare economic information with stakeholders BEFORE FDA approval can help improve payers' ability to plan for future healthcare costs



 Establishing metrics for outcomes-based contracts is currently limited to product label primary endpoints which may not align with payers' preferences









Thank You





